GERON CORP (GERN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 70.33M USD | Liabilities, Current |
| Cash and equivalents | 62.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 51.64M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 123.60M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $70.33M | $62.64M | (m) | $51.64M | $123.60M | (m) |
| 2026-03-31 | (m) | $73.57M | $68.89M | (m) | $41.88M | $133.29M | (m) |
| 2025-12-31 | (m) | $111.54M | $77.56M | (m) | $36.99M | $116.64M | (m) |
| 2025-09-30 | (m) | $87.71M | $78.12M | (m) | $35.36M | $95.42M | (m) |
| 2025-06-30 | (m) | $64.28M | $77.73M | (m) | $36.61M | $69.13M | (m) |
| 2025-03-31 | (m) | $63.03M | $83.75M | (m) | $31.17M | $56.22M | (m) |
| 2024-12-31 | $442.51M | $88.30M | $79.02M | $327.55M | $35.95M | $38.71M | 5.01× |
| 2024-09-30 | $367.78M | $137.93M | $60.34M | $279.43M | $28.01M | $20.28M | 2.67× |
| 2024-06-30 | $363.61M | $103.54M | $116.94M | $245.79M | $874.00K | $774.00K | 3.51× |
| 2024-03-31 | (m) | $123.16M | $189.76M | $253.29M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $108.07M | $70.02M | $263.68M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $89.39M | $30.71M | $282.82M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $72.57M | $56.90M | $314.48M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $43.91M | $112.78M | $267.96M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $76.69M | $56.84M | $115.90M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $82.81M | $61.10M | $133.68M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $46.88M | $76.06M | $143.23M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $46.63M | $31.32M | $135.34M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $45.52M | $34.87M | $148.85M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $38.47M | $29.04M | $147.08M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $37.01M | $57.28M | $140.96M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $28.55M | $31.54M | $179.49M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $30.94M | $9.93M | $186.35M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $24.15M | $44.96M | $182.67M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $19.14M | $22.86M | $195.88M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $16.92M | $20.29M | $111.82M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $28.16M | $13.64M | $125.68M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $11.86M | $20.75M | $117.86M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $9.18M | $17.71M | $134.78M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $6.25M | $6.80M | $145.18M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $7.55M | $10.57M | $152.71M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $4.47M | $12.73M | $153.62M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $4.91M | $19.13M | $141.80M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $4.38M | $7.91M | $81.87M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $6.52M | $16.34M | $78.35M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $5.97M | $9.90M | $86.99M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $11.27M | $6.61M | $88.24M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $11.60M | $14.86M | $84.43M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $7.87M | $12.81M | $102.03M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $7.32M | $5.88M | $102.66M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $7.11M | $8.20M | $102.40M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $6.66M | $12.80M | $96.85M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $6.63M | $21.25M | $92.52M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $6.13M | $16.82M | $102.86M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $40.73M | $15.80M | $122.21M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $40.63M | $10.18M | $135.66M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $41.80M | $42.80M | $108.64M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $7.07M | $7.60M | $118.80M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $4.76M | $9.52M | $130.82M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $4.52M | $11.32M | $133.87M | (m) | (m) | (m) |
| 2013-12-31 | (m) | $7.59M | $12.99M | $52.23M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $6.84M | $9.59M | $56.62M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $5.00M | $8.83M | $61.97M | (m) | (m) | (m) |
| 2013-03-31 | (m) | $6.79M | $15.51M | $63.53M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $14.15M | $22.06M | $73.47M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $11.26M | $16.01M | $84.44M | (m) | (m) | (m) |
| 2012-06-30 | (m) | $11.99M | $14.12M | $104.05M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $10.27M | $19.03M | $100.39M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $13.44M | $16.11M | $105.21M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $10.00M | $33.98M | $108.13M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $9.27M | $32.02M | $119.76M | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $35.41M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $40.85M | $45.97M | $140.60M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $34.49M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $37.31M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $34.60M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $109.35M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |